DNA (deoxyribonucleic acid) in tumor cells (DNA)

DNA within tumor cells is not itself a conventional therapeutic target such as an enzyme or receptor. However, it is the **critical molecular substrate** for ionizing radiation therapy. Ionizing radiation damages tumor cell DNA through several mechanisms: • Directly breaking chemical bonds within the sugar-phosphate backbone, resulting in single-strand breaks (SSBs) and double-strand breaks (DSBs), which are particularly lethal if unrepaired[2][3][4]. • Inducing base modifications and apurinic/apyrimidinic sites. • Generating clusters of complex lesions—multiple types of damage localized within short stretches—which are more difficult for cellular repair machinery to resolve than isolated lesions[3][5]. • Indirectly producing reactive oxygen species that oxidize bases or cause strand scission. The biological consequences include activation of cell cycle checkpoints, engagement of various repair pathways such as homologous recombination and nonhomologous end joining, apoptosis if damage is irreparable, or mutagenesis if misrepaired. The effectiveness—and selectivity—of radiotherapy depends on differences between tumor and normal tissue responses to this induced damage. While "tumor cell DNA" is not a specific protein target but rather a molecular substrate affected by therapy, its integrity underlies both therapeutic efficacy against cancer cells and risks for adverse effects due to collateral injury in healthy tissues. Thus it does not fit standard definitions for canonical drug targets like receptors or enzymes; instead it represents the **site-of-action** for ionizing radiation-based therapies rather than being itself a "target" molecule per se[4].

Other names

Tumor cell DNAcellular DNAgenomic DNA in cancer cells

Induction of single-strand breaks and double-strand breaks in the DNA backbone; Generation of base damage and clustered lesions; Formation of reactive oxygen species leading to indirect oxidative damage.